Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Derazantinib food-effect and rabeprazole interaction study in healthy male volunteers
NL-OMON48122Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of derazantinib and rabeprazole in intrahepatic cholangiocarcinoma (ICC) (4 arms), sponsored by Basilea Pharmaceutica. Primary endpoints: Plasma derazantinib concentrations, Plasma rabeprazole concentrations and 11 more. Started May 2019; status: completed.
02
Drugs
derazantinibrabeprazole
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NL-OMON48122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48122.